Ribociclib (1211441-98-3) is a clinically useful, potent, and specific CDK4/6 inhibitor.1,2,3 It was recently approved for use in HR+, HER2- metastatic breast cancer.
1) Rader et al. (2013), Dual CDK4/6 inhibition induces cell-cycle arrest and senescence in neuroblastoma; Clin. Cancer Res. 19 6173
2) Kim et al. (2013), LEE011: an orally bioavailable, selective small-molecule inhibitor of CDK4/6 – reactivating Rb in cancer; Mol. Cancer Ther. 12 PR02
3) Tripathy et al. (2017), Ribociclib(LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors; Clin. Cancer Res. March 28, 2017